sintilimab
eli lilly
['sintilimab', 'lcsm,(-blcsm)']
neoscore: interesting study trying to de-escalate neoadjuvant treatment - two vs. three cycles of neoadjuvant chemo-io with w/sintilimab, however lower mpr rates with two cycles (26.9% vs 41.4%), higher mpr rate in scc #asco22 #lcsm 
MD, PhD - Asst Prof, Thoracic Oncology & Precision Medicine Unit Coordinator (CEMIC). Co-Founder PxMedica: https://t.co/6HpAi0RR9P